Quest PharmaTech Inc. (CVE:QPT – Get Free Report) shares reached a new 52-week low during mid-day trading on Friday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 10798 shares. The stock had previously closed at C$0.03.
Quest PharmaTech Stock Performance
The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35. The firm has a market cap of C$3.38 million, a price-to-earnings ratio of 0.67 and a beta of -0.07. The stock has a fifty day moving average price of C$0.03 and a 200 day moving average price of C$0.03.
Quest PharmaTech Company Profile
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Featured Stories
- Five stocks we like better than Quest PharmaTech
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
